Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. - Wikidata - awgldk - TriplyDB

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q36776428

about

JAK2 activation by growth hormone and other cytokines Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Modulation of hepcidin to treat iron deregulation: potential clinical applications.Mouse models for gastric cancer: Matching models to biological questions.Therapeutic targeting of the Jak/STAT pathway.What does the aromatic ring number mean for drug design?Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.Rhodium complexes as therapeutic agents.Signaling pathways as therapeutic targets in biliary tract cancer.Kinase signaling and targeted therapy for primary myelofibrosis.STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Tyk2 is a therapeutic target for psoriasis-like skin inflammation.Management of myelofibrosis: JAK inhibition and beyond.Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer.Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.Idiopathic myelofibrosis accompanied by peritoneal extramedullary hematopoiesis presenting as refractory ascites in a dog.Ruxolitinib-associated infections: A systematic review and meta-analysis.Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress.Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma

P2860

Q27003058-6EB30D1D-5D6B-4451-BBE5-CE3AEEDD7237 Q34301568-8DB4A4BB-356F-4C98-BA72-299839AE7724 Q35214530-3BB343A7-0016-4307-9A55-25A92920D7F2 Q35484880-0EB18E62-18EF-450D-AE05-64C1144E7F5E Q35579660-0F5E6405-3B70-48F3-8E26-F1028B5E3F9A Q35727453-D70ED3BB-3D06-4FD8-A4B3-35405D506DB2 Q35735663-8B6A0B85-C738-4277-B0FD-CA3A3F3451B0 Q36210845-7BFBDC39-0781-463C-A255-D20CF364D677 Q36782943-BDD8B502-0E81-4857-944B-4E48CEE46B1C Q36847852-4E804001-4E29-4F32-B6ED-E1206B0E9FC4 Q37664258-17FFD626-491F-4639-80BF-C36B1C4F4FF0 Q38155957-F853D321-1DF1-4FC6-8019-3DC74E50AA44 Q38222473-A78E1826-F3A5-4888-A0B1-E9C74AA5A8D8 Q38418171-32D6990C-2B17-4F4D-876F-720E2F44EB89 Q38690083-D5DD7CE0-AC63-41DF-9091-953572D65553 Q38747573-58EAA118-DDB2-4A6F-99E1-A2517EBC6C04 Q38775472-DFA6A094-705E-464E-9E95-FEB73ECA132B Q38844774-37090F62-A900-4931-A3EC-2EDDF676D789 Q38887338-5AE4D1BD-6D4C-476F-A034-E94E9E8747FE Q38924086-592C3A36-26F3-4514-9640-7EF67716C185 Q38989374-EB37DDB7-88F2-4DED-AACB-135F2B999D08 Q39042555-81013DEF-1CEF-456D-A06D-DD41371F14A8 Q39232415-F5D4FB98-E41D-4DF0-97F6-67907D82232E Q40795436-16E44EFC-6279-4AE9-9BCB-C40CE0212F34 Q42365255-ECD14A98-3208-4152-9411-9F70C0D2438D Q42827073-DE57442F-1C58-47E9-8D9C-6A355F83891C Q46444617-72C06395-E21E-47AA-A4AE-BDD3B5792C23 Q47938768-2BCC5191-26CD-4151-BDFE-371F603172F6 Q48278553-7301FB42-5F1E-4C99-BC32-BF7F0A652453 Q49362075-2833AFF4-E4D9-4688-9ABD-C17AC679D920 Q50088094-38A8A953-F4C4-4041-90FA-97E7B0145B54 Q52562955-D39183F5-1E0B-458B-A6E7-09545D4C585D Q54957638-BE0FC7ED-FF98-4E32-B98D-C37CB1929641 Q54978736-5CB8B552-2CA8-4286-AAFC-8982D450EB4A Q58690869-092D371D-8827-46D3-B713-B8A3A727A219

P2860

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q36776428

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@ast

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@en

type

label

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@ast

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@en

prefLabel

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@ast

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

@en

P1433

Q36776428-E01718F6-0B12-40A8-B26D-20592738E916

P1476

Q36776428-34948372-4819-4E35-856F-BB9B6789D586

P2093

Q36776428-6E1771EB-2F6A-44B0-8A0F-51DB2D8FA276

Q36776428-ACCC9A67-CCBA-4E54-8ADD-67B332579AFB

Q36776428-B174B1F9-EE4D-4A22-B5A7-AB8C72D804E3

Q36776428-BAABC075-E153-42AC-84C4-5563B630A390

Q36776428-DCADB184-1411-4791-8DB1-E509049ED58C

P2860

Q36776428-01B08E85-48F4-4ECD-88D3-F53B8F553EA7

Q36776428-01F4EFC7-39F2-4FE4-82B0-B95AA6617853

Q36776428-0D2BE73F-A6BC-44D2-B524-2994E12809BF

Q36776428-12D1D44D-9583-4E72-B0D1-E703E473F5B1

Q36776428-1E3C2F1C-7E9D-41A2-B700-C34909DB5583

Q36776428-214370F5-3CDD-47C6-9E23-C9D373F2560B

Q36776428-22C0A938-0E57-497C-BFBF-38AB082C97E2

Q36776428-28195531-9750-4AAB-8526-B4871CF02E52

Q36776428-29574C5B-976F-4CA5-9EEE-361E30398193

Q36776428-2B644613-075E-451A-ACD5-80B54E2F39D4

P304

Q36776428-1E5B04C3-FE1B-40C4-A4F1-AF06AB4B8061

P31

Q36776428-F676A9A9-1DB5-4BFC-A95E-A47C6D3BF422

P356

Q36776428-DF07E8D5-B110-497C-AF57-B6C4057863EA

P433

Q36776428-E0970A59-EA02-490B-8D8E-8AF2A05FE73F

P478

Q36776428-D6BFC81E-D287-4D1A-BFCE-E92B91D634C2

P50

Q36776428-22CA59B7-9BEE-4D7D-B28A-FB2045DC98CA

P577

Q36776428-65F13C89-44BD-4D3C-BE02-7272390EF2F1

P5875

Q36776428-72A497F2-BEFC-40BB-8B84-BE220A631260

P698

Q36776428-3C34B6AA-EDBF-43CE-87B8-A24D243C6DB8

P932

Q36776428-126EF818-6CA8-474D-BE90-0F283FE44C3B

P356

2040620712461047

P1433

Therapeutic advances in hematology

P1476

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms

@en

P2093

Ahmad Zarzour

http://www.w3.org/2001/XMLSchema#string

Belal Firwana

http://www.w3.org/2001/XMLSchema#string

Mohammad Morad

http://www.w3.org/2001/XMLSchema#string

Ramon V Tiu

http://www.w3.org/2001/XMLSchema#string

Vishal Rana

http://www.w3.org/2001/XMLSchema#string

P2860

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Therapeutic targeting of Janus kinases

Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

P304

15-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620712461047

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Mohamad Bassam Sonbol

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236175522

http://www.w3.org/2001/XMLSchema#string

P698

23610611

http://www.w3.org/2001/XMLSchema#string

P932

3629759

http://www.w3.org/2001/XMLSchema#string